Europe’s pharmaceutical manufacturing sector operates under the most harmonised GMP regulatory framework in the world. EudraLex Volume 4 — the EU GMP guideline maintained by the European Medicines Agency (EMA) — governs pharmaceutical manufacturing facilities across all EU member states, enforced through national competent authority (NCA) inspections in each country: ANSM in France, BfArM and PEI in Germany, AIFA in Italy, INFARMED in Portugal, AEMPS in Spain, and equivalent bodies across the EU.
The 2022 revision of Annex 1 — covering sterile product manufacture — and the continuing evolution of Annex 2 (biologics) have placed renewed emphasis on facility design as a primary compliance instrument. For pharmaceutical manufacturers, contract manufacturers (CMOs), and laboratory operators across the EU, the physical environment is not background context for GMP compliance. It is a central compliance variable.
This article examines what is driving facility compliance investment across European pharmaceutical and laboratory operations, which environmental control requirements are most frequently assessed during EMA-framework inspections, and how CPL Group’s engineered solutions address those requirements.
The European regulatory landscape for pharmaceutical and laboratory facilities
All pharmaceutical manufacturers supplying the EU market must comply with EudraLex Volume 4 and hold a relevant manufacturing authorisation from their national competent authority. The framework aligns with PIC/S Guide PE 009, ensuring mutual recognition with inspection authorities in the US (FDA), UK (MHRA), Australia (TGA), and New Zealand (Medsafe).
Laboratory environments are governed by ISO 14644 for clean room classification. Research and testing laboratories seeking national accreditation operate under EN ISO/IEC 17025 frameworks. Advanced therapy medicinal product (ATMP) facilities are subject to additional requirements under Annex 2 and the EMA ATMP regulatory pathway.
Three compliance themes dominate European pharmaceutical facility investment:
- Contamination Control Strategy implementation — the 2022 Annex 1 revision mandated a formal CCS covering physical design, personnel flow, environmental monitoring, and cleaning across sterile and increasingly non-sterile manufacturing.
- Environmental separation and zone integrity — the practical facility implementation of GMP zone classification, with physical barriers and controlled access replacing reliance on procedural controls.
- Cold chain and storage compliance — particularly relevant for biologics, ATMPs, mRNA products, and the growing portfolio of temperature-sensitive medicines entering European markets.
CPL Group pharmaceutical and laboratory solutions — the full range
Clean Room Solutions
CPL Group’s Clean Room Solutions are purpose-built for pharmaceutical manufacturing and laboratory environments where contamination control is a regulatory requirement, not a preference. Systems incorporate HEPA and ULPA filtration to remove 99.99% of airborne particles, with design options that support ISO 14644 clean room classification and GMP compliance. Fully customisable in size and configuration — from compact QC lab clean rooms to large-scale sterile manufacturing suites — with modular construction that allows future reconfiguration as production requirements evolve.
Laboratory Dividers
CPL Group’s Laboratory Dividers are engineered to create defined, controlled zones within pharmaceutical and research laboratory environments. By establishing clear physical separation between workstations, sampling areas, and reagent storage, Laboratory Dividers reduce cross-contamination risk, support personnel traffic management, and contribute to GMP compliance by maintaining zone integrity during inspections. Available in a range of sizes and configurations to suit diverse laboratory floor plans, with clean, smooth surfaces that meet pharmaceutical hygiene standards.
Freezer Panels
For pharmaceutical facilities requiring reliable cold storage — whether for temperature-sensitive APIs, biological samples, reagents, or finished product — CPL Group’s Freezer Panels provide the insulated enclosure performance needed to maintain precise temperature control. Panels are engineered for pharmaceutical-grade cold store applications, supporting validated storage conditions for Schedule 4 and Schedule 8 products, biologic compounds, and clinical trial materials.
Cross Contamination Solutions
Pharmaceutical facilities running multiple product lines, handling potent compounds, or operating under changeover protocols face a heightened cross-contamination risk that layout alone cannot resolve. CPL Group’s Cross Contamination Solutions provide engineered physical barriers that prevent airborne particulate, chemical vapour, and personnel-borne contamination from crossing between zones — supporting GMP requirements for dedicated processing areas and audit-ready contamination control documentation.
Decontamination Curtains
CPL Group’s Decontamination Curtains create defined entry and egress zones that support contamination control protocols in pharmaceutical manufacturing and laboratory settings. Used at the interface between clean and controlled zones, gowning areas, and production suites, Decontamination Curtains provide a physical, auditable barrier that reinforces personnel flow protocols and reduces the risk of particulate or microbial ingress.
Chemical Splash Curtains
In pharmaceutical and laboratory environments handling solvents, reagents, and hazardous chemical inputs, Chemical Splash Curtains provide a critical layer of personnel and equipment protection. CPL Group’s chemical-resistant curtain systems are designed to contain splash events, isolate chemical handling areas, and support safe working procedures in line with WHS and laboratory safety regulations.
PVC Strip Curtains
CPL Group’s PVC Strip Curtains are deployed in pharmaceutical facilities to manage personnel and material flow between zones while maintaining environmental separation. Suitable for doorways between controlled and non-controlled areas, production entry points, and cold store access, PVC Strip Curtains reduce air exchange between zones — supporting temperature control, contamination management, and energy efficiency without impeding operational throughput.
Annex 1 and the Contamination Control Strategy across EU member states
The 2022 Annex 1 revision applies to all pharmaceutical manufacturers supplying the EU market, regardless of country of manufacture. For facilities within the EU, national competent authorities enforce the requirement for a documented CCS during site inspections. For facilities outside the EU supplying the EU market, EMA mutual recognition inspection arrangements mean the same requirement applies in practice.
The CCS requires that facilities demonstrate a systematic, documented approach to contamination prevention — with the physical environment forming the foundation of that approach. Engineered zone separation, controlled access interfaces, air pressure differential systems, and validated environmental monitoring all contribute to a defensible CCS. CPL Group’s product range provides the physical infrastructure that an audit-ready CCS demands.
Key takeaways
- EudraLex Volume 4 GMP — enforced by national competent authorities across the EU — requires a documented Contamination Control Strategy in which the physical facility environment plays a central compliance role.
- CPL Group’s pharmaceutical and laboratory product range addresses contamination prevention, zone separation, cold chain compliance, and personnel flow control across European GMP and ISO 14644 requirements.
- CPL Group supplies and installs across Europe. Contact the European and UK team on +44 777 111 5472.
Frequently Asked Questions
What regulatory standards apply to pharmaceutical facilities in Europe?
Pharmaceutical manufacturers supplying the EU market must comply with EudraLex Volume 4 — the EU GMP guidelines maintained by the EMA. Key annexes include Annex 1 (sterile products — 2022 revision) and Annex 2 (biologics). National competent authorities enforce GMP in each member state: ANSM (France), BfArM/PEI (Germany), AIFA (Italy), INFARMED (Portugal), AEMPS (Spain). Clean room environments are assessed against ISO 14644. Accredited laboratories operate under EN ISO/IEC 17025.
Does the 2022 Annex 1 revision apply to facilities outside the EU supplying the EU market?
Yes. Under EMA mutual recognition inspection arrangements and import batch release requirements, pharmaceutical facilities outside the EU supplying the EU market must comply with EudraLex Volume 4 GMP — including the Annex 1 CCS requirement. This applies to facilities in the UK (post-Brexit, under MHRA mutual recognition), the US, Australia, New Zealand, and other jurisdictions with EMA-recognised inspection authorities.
What ISO classifications do CPL Group’s Clean Room Solutions support?
CPL Group’s Clean Room Solutions are designed and built to support ISO 14644-1 classification requirements from ISO Class 5 through ISO Class 8, covering the full range of pharmaceutical manufacturing and laboratory environments from aseptic fill-finish to general QC laboratories. The specific filtration specification, air change rates, and pressure differential configuration are determined during the facility design phase based on the intended process classification.
How do CPL Group’s solutions support GMP compliance?
CPL Group’s pharmaceutical and laboratory systems are designed to support Good Manufacturing Practice (GMP) compliance across multiple dimensions: controlled airflow and pressure differentials through Clean Room Solutions, physical zone separation through Laboratory Dividers and Cross Contamination Solutions, personnel and material flow control through Decontamination Curtains and PVC Strip Curtains, and temperature-validated storage through Freezer Panels. The integrated suite allows facilities to address GMP requirements across facility layout, environmental control, and contamination management within a single supply relationship.
Can CPL Group solutions be configured for existing facilities?
Yes. CPL Group’s pharmaceutical and laboratory product range is modular and configurable for both new-build facilities and existing site retrofits. Laboratory Dividers, Cross Contamination Solutions, Decontamination Curtains, and PVC Strip Curtains can all be specified and installed within operational facilities with minimal disruption. Clean Room Solutions and Freezer Panels are designed to specification during a consultation and survey process. CPL Group provides no-obligation consultation to assess site requirements and develop a tailored solution.
How do I request a quote from CPL Group?
Contact CPL Group directly via the website or the regional office number for your country. CPL Group provides no-obligation quotes and free consultations. For pharmaceutical and laboratory projects, early engagement is recommended to allow adequate time for design consultation, site survey where required, and product specification ahead of facility commissioning or audit deadlines.
As EU GMP expectations continue to evolve, facility design is increasingly recognised as a key factor in maintaining contamination control and inspection readiness in day-to-day operations.
If you are planning a new facility or reviewing an existing site, CPL Group can support you with engineered pharmaceutical and laboratory solutions aligned with EU GMP requirements. Contact the team to discuss your project or request a consultation.
